Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 14/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3047866 | 1.00 | GHSR (0.84) | GHSR | |
| SCHEMBL29361173 | 1.00 | GHSR (0.84) | GHSR | |
| SCHEMBL29405784 | 1.00 | GHSR (0.84) | GHSR | |
| SCHEMBL17264095 | 1.00 | GHSR (0.84) | GHSR | |
| SCHEMBL13222050 | 0.97 | GHSR (0.85) | GHSR | |
| SCHEMBL13222048 | 0.97 | GHSR (0.85) | GHSR | |
| SCHEMBL18488497 | 0.96 | GHSR (0.78) | GHSR | |
| SCHEMBL13222102 | 0.95 | GHSR (0.91) | GHSR | |
| SCHEMBL13222108 | 0.95 | GHSR (0.91) | GHSR | |
| SCHEMBL29546807 | 0.95 | GHSR (0.90) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394833-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394833-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8288427-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288427-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120232113-A1 | METHODS OF TREATING EMESIS USING GROWTH HORMONE SECRETAGOGUES | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120077745-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077745-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-8039457-B2 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100087381-A1 | Method of Stimulating the Motility of the Gastrointestinal System Using Growth Hormone Secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20080300194-A1 | Methods of treating emesis using growth hormone secretagogues | SAPPHIRE THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300194-A1 | Methods of treating emesis using growth hormone secretagogues | SAPPHIRE THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080207640-A1 | Method of treating cell proliferative disorders using growth hormone secretagogues | SAPPHIRE THERAPEUTICS (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207640-A1 | Method of treating cell proliferative disorders using growth hormone secretagogues | SAPPHIRE THERAPEUTICS (US) | 2008-08-28 | — | — | US | disclosed |
| US-20070191283-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | REJUVENON CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191283-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | REJUVENON CORPORATION | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077745-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | GHSR, GHRHR, MLNR | GHSR 1/4885 |
| US-20120232113-A1 | METHODS OF TREATING EMESIS USING GROWTH HORMONE SECRETAGOGUES | GHSR, GHRHR, CRH | GHSR 1/4885 |
| US-20080300194-A1 | Methods of treating emesis using growth hormone secretagogues | GHSR, GHRHR, CRH | GHSR 1/4885 |
| US-20100087381-A1 | Method of Stimulating the Motility of the Gastrointestinal System Using Growth Hormone Secretagogues | GHSR, GHRHR, MLNR | GHSR 1/4885 |
| US-20080207640-A1 | Method of treating cell proliferative disorders using growth hormone secretagogues | GHSR, GHRHR, SSTR5 | GHSR 1/4885 |
| US-20070191283-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | GHSR, GHRHR, MLNR | GHSR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.